WELLINGTON MANAGEMENT GROUP LLP - CRINETICS PHARMACEUTICALS IN ownership

CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 84 filers reported holding CRINETICS PHARMACEUTICALS IN in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.5%.

Quarter-by-quarter ownership
WELLINGTON MANAGEMENT GROUP LLP ownership history of CRINETICS PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$108,260,589
+66.8%
3,640,235
+1.1%
0.02%
+83.3%
Q2 2023$64,902,849
+11.2%
3,601,712
-0.9%
0.01%0.0%
Q1 2023$58,386,547
+13.8%
3,635,526
+29.6%
0.01%
+20.0%
Q4 2022$51,322,076
-0.8%
2,804,485
+6.5%
0.01%
-9.1%
Q3 2022$51,713,000
+52.1%
2,633,011
+44.4%
0.01%
+57.1%
Q2 2022$34,010,000
+50.5%
1,823,598
+77.2%
0.01%
+75.0%
Q1 2022$22,595,000
-25.7%
1,029,364
-3.8%
0.00%
-20.0%
Q4 2021$30,407,000
+58.2%
1,070,272
+17.2%
0.01%
+66.7%
Q3 2021$19,220,000
+36.8%
913,071
+22.5%
0.00%
+50.0%
Q2 2021$14,051,000
+66.5%
745,387
+35.0%
0.00%
+100.0%
Q1 2021$8,437,000
+7.4%
552,167
-0.8%
0.00%0.0%
Q4 2020$7,854,000
+14.5%
556,635
+27.2%
0.00%0.0%
Q3 2020$6,860,000
+25.8%
437,756
+40.6%
0.00%0.0%
Q2 2020$5,453,000311,2810.00%
Other shareholders
CRINETICS PHARMACEUTICALS IN shareholders Q2 2021
NameSharesValueWeighting ↓
Saturn V Capital Management LP 1,126,579$33,504,45914.02%
New Leaf Venture Partners, L.L.C. 141,000$4,193,3405.38%
First Light Asset Management, LLC 1,583,329$47,088,2044.47%
Paradigm Biocapital Advisors LP 2,178,737$64,795,6384.40%
Bain Capital Life Sciences Investors, LLC 1,275,552$37,934,9164.24%
Altium Capital Management LP 262,000$7,791,8804.06%
5AM Venture Management, LLC 462,286$13,748,3863.96%
MPM BioImpact LLC 479,053$14,247,0363.80%
Affinity Asset Advisors, LLC 450,000$13,383,0003.76%
Opaleye Management Inc. 370,000$11,003,8003.58%
View complete list of CRINETICS PHARMACEUTICALS IN shareholders